In vivo tumor targeting of gold nanoparticles: Effect of particle type and dosing strategy

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 1251-1258

  Puvanakrishnan, Priyaveena ^a   Park, Jaesook ^a   Chatterjee, Deyali ^b   Krishnan, Sunil ^b   Tunnell, James W ^a  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Gold nanorods; Gold nanoshells; Multiple dosing; Tumor targeting

Indexed keywords

GOLD; GOLD NANOPARTICLE; GOLD NANOROD; PEGYLATED GOLD NANOSHELL; UNCLASSIFIED DRUG; DRUG CARRIER; METAL NANOPARTICLE; NANOTUBE;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG LIVER LEVEL; DRUG SAFETY; DRUG TARGETING; DRUG TUMOR LEVEL; DRUG UPTAKE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; NEUTRON ACTIVATION ANALYSIS; NONHUMAN; PARTICLE SIZE; TOXICITY TESTING; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; CYTOCHEMISTRY; DRUG DELIVERY SYSTEM; DRUG SCREENING; LIVER; METABOLISM; METHODOLOGY; MOUSE; NEOPLASM; NUDE MOUSE; SPLEEN; TUMOR CELL LINE;

MUS;

ANIMALS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GOLD; HISTOCYTOCHEMISTRY; HUMANS; LIVER; METAL NANOPARTICLES; MICE; MICE, NUDE; NANOTUBES; NEOPLASMS; SPLEEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862323547     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S29147     Document Type: Article

References (34)

1. Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol. 2003;3(3):319-328.
2. Goodrich G, Bao L, Gill-Sharp K, Sang K, Wang J, Payne JD. Photothermal therapy in a murine colon cancer model using nearinfrared absorbing gold nanorods. J Biomed Opt. 2010;15(1):018001.
3. Loo C, Lowery A, Halas N, West J, Crezek R. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett. 2005;5(4): 709-711.
4. Sokolov K, Follen M, Aaron J, et al. Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res. 2003;63(9): 1999-2004.
5. Loo C, Hirsch L, Lee MH, et al. Gold nanoshell bioconjugates for molecular imaging in living cells. Opt Lett. 2005;30(9):1012-1014.
6. Choi CH, Alabi CA, Webster P, Davis ME. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A. 2010;107(3):1235-1240.
7. Williams KJ, Telfer BA, Stratford IJ, Wedge SR. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer. 2002;86(7):1157-1161.
8. Kato T, Sato K, Kakinuma H, Matsuda Y. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res. 1994;54(19):5143-5147.
9. Santini D, Vincenzi B, La Cesa A, et al. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study. Anticancer Res. 2005;25(1B):669-674.
10. Schluep T, Hwang J, Cheng J, et al. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res. 2006;12(5):1606-1614.
11. Herbst RS, Maddox AM, Rothenburg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 2002;20(18):3815-3825.
12. Hirsch LR, Stafford RJ, Bankson JA, et al. Nanoshell-mediated nearinfrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A. 2003;100(23):13549-13554.
13. Huang X, El-Sayed IH, Qian W, El-Sayed MA. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc. 2006;128(6):2115-2120.
14. De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJ, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials. 2008;29(12):1912-1919.
15. Terentyuk GS, Maslyakova GN, Suleymanove LV, et al. Circulation and distribution of gold nanoparticles and induced alterations of tissue morphology at intravenous particle delivery. J Biophotonics. 2009;2(5):292-302.
16. Melancon MP, Lu W, Yang Z, et al. In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy. Mol Cancer Ther. 2008;7(6):1730-1739.
17. Wang J, Byrne JD, Napier ME, DeSimone JM. More effective nanomedicines through particle design. Small. 2011;7(14):1919-1931.
18. Nomura T, Koreeda N, Yamashita F, Takakura Y, Hashida M. Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors. Pharm Res. 1998;15(1):128-132.
19. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 2005;65(19):8984-8992.
20. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771-782.
21. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 2009;9(5):1909-1915.
22. Oldenburg SJ, Averitt RD, Westcott SL, Halas NJ. Nanoengineering of optical resonances. Chem Phys Letters. 1998;288:243-247.
23. Jana NR, Geargart L, Murphy CJ. Wet chemical synthesis of high aspect ratio cylindrical gold nanorods. J Physl Chem B. 2001;105(19): 4065-4067.
24. James WD, Hirsch LR, West JL, O'Neal PD, Payne JD. Application of INAA to the build-up and clearance of gold nanoshells in clinical studies in mice. J Radio Nucl Chem. 2007;271:455-459.
25. Bartlett DW, Davis ME. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol Bioeng. 2008;99(4):975-985.
26. O'Neal DP, Hirsch LR, Halas NJ, Payne JD, West JL. Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett. 2004;209(2):171-176.
27. Puvanakrishnan P, Diagaradjane P, Kazmi SM, Dunn AK, Krishnan S, Tunnell JW. Narrow band imaging of squamous cell carcinoma tumors using topically delivered anti-EGFR antibody conjugated gold nanorods. Lasers Surg Med. In press.
28. Park J, Estrada A, Schwartz JA, et al. Intra-organ biodistribution of gold nanoparticles using intrinsic two-photon induced photoluminescence. Lasers Surg Med. 2010;42(7):630-639.
29. Puvanakrishnan P, Park J, Diagaradjane P, et al. Near-infrared narrow band imaging of gold/silica nanoshells in tumors. J Biomed Opt. 2009;14(2):024044.
30. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng. 1999;1:241-263.
31. Jain Rk, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988;48(24 Pt 1): 7022-7032.
32. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissueisolated and subcutaneous tumors: implications for therapy. Cancer Res. 1990;50(15):4478-4484.
33. Choi HS, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25(10):1165-1170.
34. Hobbs SK, Monsky WL, Yuan R, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A. 1998;95(8):4607-4612.